OBJECTIVE: To characterize [11 C]-PBR28 brain uptake using positron emission tomography (PET) in people with amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS). We have previously shown increased [11 C]-PBR28 uptake in the precentral gyrus in a small group of ALS patients. Herein, we confirm our initial finding, study the longitudinal changes, and characterize the gray versus white matter distribution of [11 C]-PBR28 uptake in a larger cohort of patients with ALS and PLS. METHODS: Eighty-five participants including 53 with ALS, 11 with PLS, and 21 healthy controls underwent integrated [11 C]-PBR28 PET-magnetic resonance brain imaging. Patients were clinically assessed using the Upper Motor Neuron Burden (UMNB) and the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R). [11 C]-PBR28 uptake was quantified as standardized uptake value ratio (SUVR) and compared between groups. Cortical thickness and fractional anisotropy were compared between groups and correlated with SUVR and the clinical data. [11 C]-PBR28 uptake and ALSFRS-R were compared longitudinally over 6 months in 10 ALS individuals. RESULTS: Whole brain voxelwise, surface-based, and region of interest analyses revealed increased [11 C]-PBR28 uptake in the precentral and paracentral gyri in ALS, and in the subcortical white matter for the same regions in PLS, compared to controls. The increase in [11 C]-PBR28 uptake colocalized and correlated with cortical thinning, reduced fractional anisotropy, and increased mean diffusivity, and correlated with higher UMNB score. No significant changes were detected in [11 C]-PBR28 uptake over 6 months despite clinical progression. INTERPRETATION: Glial activation measured by in vivo [11 C]-PBR28 PET is increased in pathologically relevant regions in people with ALS and correlates with clinical measures. Ann Neurol 2018;83:1186-1197.
OBJECTIVE: To characterize [11 C]-PBR28 brain uptake using positron emission tomography (PET) in people with amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS). We have previously shown increased [11 C]-PBR28 uptake in the precentral gyrus in a small group of ALSpatients. Herein, we confirm our initial finding, study the longitudinal changes, and characterize the gray versus white matter distribution of [11 C]-PBR28 uptake in a larger cohort of patients with ALS and PLS. METHODS: Eighty-five participants including 53 with ALS, 11 with PLS, and 21 healthy controls underwent integrated [11 C]-PBR28 PET-magnetic resonance brain imaging. Patients were clinically assessed using the Upper Motor Neuron Burden (UMNB) and the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R). [11 C]-PBR28 uptake was quantified as standardized uptake value ratio (SUVR) and compared between groups. Cortical thickness and fractional anisotropy were compared between groups and correlated with SUVR and the clinical data. [11 C]-PBR28 uptake and ALSFRS-R were compared longitudinally over 6 months in 10 ALS individuals. RESULTS: Whole brain voxelwise, surface-based, and region of interest analyses revealed increased [11 C]-PBR28 uptake in the precentral and paracentral gyri in ALS, and in the subcortical white matter for the same regions in PLS, compared to controls. The increase in [11 C]-PBR28 uptake colocalized and correlated with cortical thinning, reduced fractional anisotropy, and increased mean diffusivity, and correlated with higher UMNB score. No significant changes were detected in [11 C]-PBR28 uptake over 6 months despite clinical progression. INTERPRETATION: Glial activation measured by in vivo [11 C]-PBR28 PET is increased in pathologically relevant regions in people with ALS and correlates with clinical measures. Ann Neurol 2018;83:1186-1197.
Authors: S K Schimrigk; B Bellenberg; M Schlüter; B Stieltjes; R Drescher; J Rexilius; C Lukas; H K Hahn; H Przuntek; O Köster Journal: AJNR Am J Neuroradiol Date: 2007-04 Impact factor: 3.825
Authors: Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher Journal: Nat Rev Drug Discov Date: 2010-12 Impact factor: 84.694
Authors: Oleg Butovsky; Shafiuddin Siddiqui; Galina Gabriely; Amanda J Lanser; Ben Dake; Gopal Murugaiyan; Camille E Doykan; Pauline M Wu; Reddy R Gali; Lakshmanan K Iyer; Robert Lawson; James Berry; Anna M Krichevsky; Merit E Cudkowicz; Howard L Weiner Journal: J Clin Invest Date: 2012-08-06 Impact factor: 14.808
Authors: Sabrina Paganoni; Mohamad J Alshikho; Sarah Luppino; James Chan; Lindsay Pothier; David Schoenfeld; Patricia L Andres; Suma Babu; Nicole R Zürcher; Marco L Loggia; Robert L Barry; Silvia Luotti; Giovanni Nardo; Maria Chiara Trolese; Serena Pantalone; Caterina Bendotti; Valentina Bonetto; Fabiola De Marchi; Bruce Rosen; Jacob Hooker; Merit Cudkowicz; Nazem Atassi Journal: Muscle Nerve Date: 2018-12-26 Impact factor: 3.217
Authors: Daniel S Albrecht; Anton Forsberg; Angelica Sandström; Courtney Bergan; Diana Kadetoff; Ekaterina Protsenko; Jon Lampa; Yvonne C Lee; Caroline Olgart Höglund; Ciprian Catana; Simon Cervenka; Oluwaseun Akeju; Mats Lekander; George Cohen; Christer Halldin; Norman Taylor; Minhae Kim; Jacob M Hooker; Robert R Edwards; Vitaly Napadow; Eva Kosek; Marco L Loggia Journal: Brain Behav Immun Date: 2018-09-14 Impact factor: 7.217
Authors: D S Albrecht; M Kim; O Akeju; A Torrado-Carvajal; R R Edwards; Y Zhang; C Bergan; E Protsenko; A Kucyi; A D Wasan; J M Hooker; V Napadow; M L Loggia Journal: Mol Psychiatry Date: 2019-05-28 Impact factor: 15.992
Authors: Zeynab Alshelh; Daniel S Albrecht; Courtney Bergan; Oluwaseun Akeju; Daniel J Clauw; Lisa Conboy; Robert R Edwards; Minhae Kim; Yvonne C Lee; Ekaterina Protsenko; Vitaly Napadow; Kimberly Sullivan; Marco L Loggia Journal: Brain Behav Immun Date: 2020-02-04 Impact factor: 7.217
Authors: Peter M Grace; Vivianne L Tawfik; Camilla I Svensson; Michael D Burton; Marco L Loggia; Mark R Hutchinson Journal: J Neurosci Date: 2020-11-25 Impact factor: 6.167
Authors: Keith R Spencer; Zachariah W Foster; Nazifa Abdul Rauf; Latease Guilderson; Derek Collins; James G Averill; Sean E Walker; Ian Robey; Jonathan D Cherry; Victor E Alvarez; Bertrand R Huber; Ann C McKee; Neil W Kowall; Christopher B Brady; Thor D Stein Journal: Brain Pathol Date: 2020-08-04 Impact factor: 6.508
Authors: William C Kreisl; Min-Jeong Kim; Jennifer M Coughlin; Ioline D Henter; David R Owen; Robert B Innis Journal: Lancet Neurol Date: 2020-11 Impact factor: 44.182
Authors: N R Zürcher; M L Loggia; J E Mullett; C Tseng; A Bhanot; L Richey; B G Hightower; C Wu; A J Parmar; R I Butterfield; J M Dubois; D B Chonde; D Izquierdo-Garcia; H Y Wey; C Catana; N Hadjikhani; C J McDougle; J M Hooker Journal: Mol Psychiatry Date: 2020-02-19 Impact factor: 15.992
Authors: Ignacio Illán-Gala; Victor Montal; Jordi Pegueroles; Eduard Vilaplana; Daniel Alcolea; Oriol Dols-Icardo; Noemi de Luna; Janina Turón-Sans; Elena Cortés-Vicente; Luis Martinez-Roman; Maria Belén Sánchez-Saudinós; Andrea Subirana; Laura Videla; Isabel Sala; Isabel Barroeta; Sílvia Valldeneu; Rafael Blesa; Jordi Clarimón; Alberto Lleó; Juan Fortea; Ricard Rojas-García Journal: Neurology Date: 2020-09-10 Impact factor: 9.910